Overview

A Multiple Dosing (14 Days) Study to Assess Efficacy and Safety of Three Dose Levels of AZD7594, Given Once Daily by Inhalation, in Patients With Mild to Moderate Asthma

Status:
Completed

Trial end date:
2016-02-08

Target enrollment:

Participant gender:

Summary

This study will be a randomised, double-blind, multiple dose (14 days), placebo-controlled, multi-center study to assess efficacy and safety of three dose levels of AZD7594, given once daily by inhalation, in patients with mild to moderate asthma.

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Treatments:

Albuterol